Harbour BioMed (HBM) is a global, clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in the areas of immuno-oncology and immunology. They leverage their proprietary Harbour Mice® platforms (HCAb, HBICE™) for generating fully human monoclonal antibodies. Their pipeline includes promising candidates like Batoclimab (HBM9161) and Porustobart (HBM4003), targeting a range of autoimmune diseases and cancers. HBM aims to address unmet medical needs and bring transformative therapies to patients worldwide.
The Suzhou headquarters serves as the central hub for Harbour BioMed's global operations, including strategic leadership, core R&D activities, corporate functions, and coordination with its international sites.
Located within BioBAY, the facility benefits from a vibrant ecosystem of biotech companies, research institutions, and talent. It likely features state-of-the-art laboratory spaces for antibody discovery and development.
The work culture emphasizes scientific rigor, innovation, and collaboration. As a global company, it fosters an international mindset, with teams working on cutting-edge biopharmaceutical research aimed at addressing significant unmet medical needs.
Its location in Suzhou's BioBAY positions Harbour BioMed at the forefront of China's rapidly growing biotech industry, facilitating access to local talent, research collaborations, and the Chinese pharmaceutical market, while also serving as a base for global expansion.
Harbour BioMed maintains a significant global presence with key operational sites in China (Suzhou and Shanghai), the United States (Cambridge, MA), and Europe (Rotterdam, Netherlands). This international footprint supports its end-to-end capabilities, from antibody discovery and development through to clinical trials and potential commercialization across major pharmaceutical markets.
Building B7, 218 Xinghu Street, Suzhou Industrial Park
Suzhou
Jiangsu Province
China
Address: 45 Spinelli Place, Cambridge, MA 02138, USA
Serves as the North American hub for advancing clinical trials, engaging with regulatory authorities like the FDA, and fostering partnerships within the U.S. biopharmaceutical industry.
Address: Rotterdam Science Tower, 10th floor, Marconistraat 16, 3029 AK Rotterdam, The Netherlands
Acts as the European operational and R&D center, facilitating research collaborations, clinical development in Europe, and engagement with the European Medicines Agency (EMA).
Address: Building 1, Lane 55, Chuanhe Road, Pudong New Area, Shanghai, China
Focuses on navigating the Chinese pharmaceutical market, managing clinical trials in China, and preparing for potential product launches in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Harbour BioMed' leadership includes:
Harbour BioMed has been backed by several prominent investors over the years, including:
In August 2023, Harbour BioMed announced the appointment of Mr. Mayank Rawat as Chief Financial Officer. No other major high-profile executive departures have been publicly announced in the last 12 months, suggesting relative stability in the senior leadership team.
Discover the tools Harbour BioMed uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Harbour BioMed's email format is most commonly [first_initial][last]@harbourbiomed.com or [first].[last]@harbourbiomed.com. For example, Jingsong Wang might be jwang@harbourbiomed.com.
[firstinitial][last]@harbourbiomed.com or [first].[last]@harbourbiomed.com
Format
jwang@harbourbiomed.com
Example
80%
Success rate
Harbour BioMed Official Website • March 7, 2024
Harbour BioMed announced that the first patient has been dosed in its Phase II clinical trial of Batoclimab (HL161B) for treating Thyroid Eye Disease (TED) in China. This marks progress in evaluating Batoclimab's efficacy for TED patients....more
Harbour BioMed Official Website • January 3, 2024
Harbour BioMed's partner, CSPC Pharmaceutical Group Limited, received NMPA approval in China for Porustobart (HBM4003) in combination with Toripalimab to treat advanced hepatocellular carcinoma (HCC). This is a significant milestone for HBM4003....more
Harbour BioMed Official Website • August 21, 2023
Harbour BioMed announced the appointment of Mr. Mayank Rawat as its Chief Financial Officer. Mr. Rawat brings over two decades of experience in finance, particularly within the biopharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Harbour BioMed, are just a search away.